Victory Capital Management Inc. Raises Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Victory Capital Management Inc. increased its position in Omnicell, Inc. (NASDAQ:OMCL) by 11,982.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,148,426 shares of the company’s stock after acquiring an additional 1,138,921 shares during the period. Victory Capital Management Inc. owned approximately 2.50% of Omnicell worth $50,071,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in OMCL. Texas Permanent School Fund Corp raised its stake in Omnicell by 1.2% in the 1st quarter. Texas Permanent School Fund Corp now owns 39,630 shares of the company’s stock worth $1,158,000 after acquiring an additional 479 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Omnicell in the 1st quarter worth about $684,000. Inspire Investing LLC boosted its holdings in Omnicell by 19.2% in the 1st quarter. Inspire Investing LLC now owns 12,111 shares of the company’s stock worth $354,000 after buying an additional 1,952 shares during the last quarter. ProShare Advisors LLC boosted its holdings in Omnicell by 7.4% in the 1st quarter. ProShare Advisors LLC now owns 9,076 shares of the company’s stock worth $265,000 after buying an additional 626 shares during the last quarter. Finally, Entropy Technologies LP acquired a new stake in Omnicell in the 1st quarter worth about $227,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Trading Down 2.0 %

Shares of OMCL stock opened at $45.67 on Friday. The firm has a fifty day moving average price of $44.19 and a 200 day moving average price of $36.70. The company has a market cap of $2.12 billion, a P/E ratio of -117.10, a PEG ratio of 46.03 and a beta of 0.81. Omnicell, Inc. has a 12 month low of $25.12 and a 12 month high of $55.74.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on OMCL shares. Bank of America reiterated a “neutral” rating and issued a $57.00 price objective (up from $44.00) on shares of Omnicell in a report on Thursday, October 31st. Benchmark restated a “buy” rating and set a $48.00 target price on shares of Omnicell in a report on Wednesday, October 9th. Barclays boosted their target price on Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Wells Fargo & Company boosted their target price on Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a report on Monday, October 14th. Finally, StockNews.com lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Friday. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $50.83.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.